The level of caveolin-1 expression determines response to TGF-ß as a tumor suppressor in hepatocellular carcinoma cells by Moreno Càceres, Joaquim et al.
OPEN
The level of caveolin-1 expression determines
response to TGF-β as a tumour suppressor in
hepatocellular carcinoma cells
Joaquim Moreno-Càceres1,6, Daniel Caballero-Díaz1,6, Zeribe Chike Nwosu2, Christoph Meyer2, Judit López-Luque1,
Andrea Malfettone1, Raquel Lastra1,3, Teresa Serrano1,4, Emilio Ramos1,3, Steven Dooley2,7 and Isabel Fabregat*,1,5,7
Hepatocellular carcinoma (HCC) is a heterogeneous tumour associated with poor prognostic outcome. Caveolin-1 (CAV1), a
membrane protein involved in the formation of caveolae, is frequently overexpressed in HCC. Transforming growth factor-beta
(TGF-β) is a pleiotropic cytokine having a dual role in hepatocarcinogenesis: inducer of apoptosis at early phases, but pro-
tumourigenic once cells acquire mechanisms to overcome its suppressor effects. Apoptosis induced by TGF-β is mediated by
upregulation of the NADPH oxidase NOX4, but counteracted by transactivation of the epidermal growth factor receptor (EGFR)
pathway. Previous data suggested that CAV1 is required for the anti-apoptotic signals triggered by TGF-β in hepatocytes. Whether
this mechanism is relevant in hepatocarcinogenesis has not been explored yet. Here we analysed the TGF-β response in HCC cell
lines that express different levels of CAV1. Accordingly, stable CAV1 knockdown or overexpressing cell lines were generated. We
demonstrate that CAV1 is protecting HCC cells from TGF-β-induced apoptosis, which attenuates its suppressive effect on
clonogenic growth and increases its effects on cell migration. Downregulation of CAV1 in HLE cells promotes TGF-β-mediated
induction of the pro-apoptotic BMF, which correlates with upregulation of NOX4, whereas CAV1 overexpression in Huh7 cells
shows the opposite effect. CAV1 silenced HLE cells show attenuation in TGF-β-induced EGFR transactivation and activation of the
PI3K/AKT pathway. On the contrary, Huh7 cells, which do not respond to TGF-β activating the EGFR pathway, acquire the capacity
to do so when CAV1 is overexpressed. Analyses in samples from HCC patients revealed that tumour tissues presented higher
expression levels of CAV1 compared with surrounding non-tumoural areas. Furthermore, a significant positive correlation among
the expression of CAV1 and TGFB1was observed. We conclude that CAV1 has an essential role in switching the response to TGF-β
from cytostatic to tumourigenic, which could have clinical meaning in patient stratification.
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Hepatocellular carcinoma (HCC) is a heterogeneous tumour
commonly associated with chronic liver diseases, such as
alcoholic and viral hepatitis, and is often preceded by
cirrhosis.1 Given the lack of an effective therapeutic approach,
several studies have focused on molecular targets that can
predict either clinical outcome or drug response. Caveolins are
a family of membrane proteins required for the formation of
membrane invaginations called caveolae. Caveolae are
involved in cellular trafficking, and have been proposed as
possible sites for mining druggable targets in cancer.2
Interestingly, in addition to the role of caveolins in caveolae
formation, they also act as scaffolding proteins, and as such
modulate intracellular signalling pathways.3 Caveolin-1
(CAV1), the mostly studied member of the family (others
being CAV2 and CAV3), functions either as a tumour
suppressor or as an oncogene, depending on tumour type
and cellular context.3 Nevertheless, in HCC several evidences
propose CAV1 as an important factor determining higher
invasive and metastatic phenotypes, as well as poor
prognosis.4–6 CAV1 expression has been found to be
increased concomitant with HCC progression. This correlates
with the fact that overexpression of CAV1 promotes HCC cell
growth, increases motility and invasiveness, as well as higher
tumourigenic potential in vivo.4,6 Interestingly, knockdown of
CAV1 in metastatic HCC cells had the opposite effect,
suppressing tumour growth and metastatic potential in vivo.6
Further, CAV1 expression varies with differentiation state of
HCC cells: well-differentiated cell lines do not express
detectable levels of CAV1, whereas high expression can be
found in poorly differentiated HCC cell lines.7 However, the
mechanism for CAV1 involvement in all these effects is not
fully understood yet.
Transforming growth factor-beta (TGF-β) is a pleiotropic
cytokine that also has a dual role in tumourigenesis. For
instance, TGF-β acts as a growth inhibitor in early stages of
cancer, but promotes progression once cells have acquired
1Bellvitge Biomedical Research Institute (IDIBELL), Oncobell Program, L‘Hospitalet de Llobregat, Barcelona, Spain; 2Molecular Hepatology Section, Department of
Medicine II, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany; 3Department of Surgery, Liver Transplant Unit, University Hospital of Bellvitge,
Barcelona, Spain; 4Pathological Anatomy Service, University Hospital of Bellvitge, Barcelona, Spain and 5Department of Physiological Sciences II, University of Barcelona,
Barcelona, Spain
*Corresponding author: I Fabregat, Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de L’Hospitalet, 199, L’Hospitalet de Llobregat, Barcelona 08908, Spain.
Tel: +34 932 607828; Fax: +34 932 607426; E-mail: ifabregat@idibell.cat
6These authors contributed equally to this work.
7Co-senior authors.
Received 15.5.17; revised 31.7.17; accepted 09.8.17; Edited by M Piacentini
Citation: Cell Death and Disease (2017) 8, e3098; doi:10.1038/cddis.2017.469
Official journal of the Cell Death Differentiation Association
www.nature.com/cddis
the mechanism to overcome its suppressor effect. Thus, in
liver tumour cells, TGF-β regulates a balance between both
pro- and anti-apoptotic signals, which is critical for cell
fate decisions.8 Cells that circumvent its pro-apoptotic action
may undergo epithelial–mesenchymal transition (EMT),9
further acquiring increased migratory10 and drug resistance
capabilities.11 Previously, we have shown that mainly poorly
differentiated HCC cell lines resist the cytostatic effect of
TGF-β.12 Overall, there is a great interest in a better under-
standing of the mechanisms that allow liver tumour cells to
preferentially respond to TGF-β pro-survival signals. CAV1
affects TGF-β/-Smad (canonical) and non-Smad (non-canonical)
signalling and thus can determine the cellular outcome upon
TGF-β challenge.13,14 Indeed, CAV1 is required for the non-
canonical signalling pathways thatmediate anti-apoptotic signals
triggered by TGF-β in hepatocytes,15,16 although nothing is
known about whether it has a similar role in HCC cells.
In this study, we more thoroughly investigated the impact of
CAV1 on the TGF-β response in HCC cell lines and found out
that CAV1 is critical to blunt the tumour-suppressor function of
TGF-β in HCC cells.
Results
CAV1 expression impairs TGF-β-induced apoptosis in
HCC cell lines. We first tested whether CAV1 has a role in
regulating the balance between pro- and anti-survival signals
in HCC cells. On the one hand, we knocked down CAV1 in
HLE cells, a poorly differentiated HCC cell line that shows high
CAV1 expression (Figure 1a). On the other hand, we
overexpressed CAV1 in Huh7 cells, a well-differentiated HCC
cell line with low basal CAV1 expression (Figure 1a). In HLE,
knockdown of CAV1 increased the percentage of TGF-β-
induced cell death in comparison with high CAV1-expressing
controls, suggesting CAV1 as an antagonist of the TGF-β-
mediated apoptotic response (Figure 1b). In line with this,
overexpression of CAV1 in Huh7 cells significantly suppressed
TGF-β-induced cell death (Figure 1c). Furthermore, we found
that TGF-β activation of caspase-3 (a pro-apoptotic mediator)
depends on the level of CAV1 expression (Figures 1d and e).
These evidences suggest that CAV1 may be protecting HCC
cells from TGF-β death-inducing signals.
Overexpression of CAV1 enables clonogenic growth and
promote cell migration under TGF-β stimulation. We next
evaluated if CAV1 expression interferes with anti-proliferative
action and facilitates tumourigenic activity of TGF-β. First, we
measured clonogenic growth upon TGF-β stimulation in HCC
cell lines with modulation in CAV1 expression. As expected
from our previous study,12 TGF-β had no effect on clonal
proliferation of HLE cells, whereas knockdown of CAV1
decreased clonogenic growth in presence of TGF-β
(Figure 2a). Consistently, the inhibitory effect of TGF-β on
clonal growth of Huh7 was counteracted in the state of
ectopic CAV1 expression (Figure 2b). Cell cycle arrest is
among the cytostatic effects induced by TGF-β.17 Hence, we
next performed flow cytometry analyses to determine
whether CAV1 would influence TGF-β effects on cell cycle.
HLE cells did not respond to TGF-β inhibiting cell cycle
progression (Table 1a; Supplementary Figure 1A). In con-
trast, Huh7 exhibited the characteristic features of cell cycle
arrest: an increase in the percentage of cells in G0/G1 phase
and a decrease in S and G2/M phases. However, this was
uninfluenced by ectopic CAV1 expression (Table 1b;
Supplementary Figure 1B). Finally, as one of the main
tumourigenic actions of TGF-β is inducing cell migration, we
explored whether silencing or overexpressing CAV1 alters the
TGF-β-migratory capability in these cells. Results indicated
that silencing CAV1 per se is enough to decrease the high
migratory capability of HLE cells (Figure 2c). Furthermore,
CAV1 overexpression promotes basal migration of Huh7 cells
and, interestingly, sensitised cells to the pro-migratory effects
of TGF-β (Figure 2d).
Taken together, results indicate that CAV1 expression
attenuates the suppressive effect of TGF-β on clonogenic
growth, which is explained by its effects on impairing
apoptosis, as it does not influence the effects of TGF-β on
cell cycle arrest. In addition, expression of CAV1, probably
through its effects mediating apoptosis resistance, favours the
HCC cell response to the pro-migratory effects of TGF-β.
CAV1 modulates TGF-β-dependent regulation of BMF,
BIM and NOX4. TGF-β controls expression of different
apoptosis regulatory proteins at both transcriptional and
post-transcriptional levels. For instance, TGF-β in context of
an apoptotic response upregulates the pro-apoptotic BCL-2
family members, BIM (BCL2L11) and BCL-2-modifying factor
(BMF).8,18 Hence, we wondered whether CAV1 has mod-
ulatory impact on TGF-β mediated regulation of BIM and
BMF. In HLE with intrinsically high basal CAV1, TGF-β-
mediated BMF induction is disrupted (Figure 3a, left panel).
However, the downstream TGF-β pathway branch could be
reactivated in HLE upon CAV1 knockdown, resulting in
significantly induced BMF expression (Figure 3a, left panel).
Consistently, TGF-β-mediated induction of BMF was
decreased in Huh7 cells with ectopic CAV1 overexpression
(Figure 3a, right panel). For BIM, no differences were
observed in response to TGF-β in HLE cells at mRNA
(Figure 3b, left panel) and protein level (data not shown),
regardless of presence or absence of CAV1 (Figure 3b, left
panel). In Huh7, CAV1 overexpression prevented upregula-
tion of BIM (BCL2L11) at mRNA and protein levels after short
term TGF-β treatment (Figure 3b, right panel and Figure 3c).
These results suggest BMF as one TGF-β-regulated BCL-2
family member consistently affected by CAV1 in the two HCC
cell lines.
Transcriptional regulation of BMF via TGF-β requires
expression of the NADPH oxidase NOX4,18 a known factor
in cellular oxidative stress that also mediates pro-apoptotic
effects in liver cells.19 We found that NOX4 levels are very low
in HLE cells, and are only slightly induced by TGF-β. However,
CAV1 knockdown resulted in a significant increase in TGF-β
stimulated NOX4 mRNA levels (Figure 4a). In the case of
Huh7 cells, interestingly, NOX4 expression was significantly
decreased in CAV1-overexpressing cells under basal condi-
tions (Figure 4b). Furthermore, TGF-β-mediated increase in
NOX4 mRNA levels was strongly impaired by CAV1 over-
expression (Figure 4b). Increased expression of NOX4 upon
TGF-β stimulation in CAV1 knockdown HLE cells was also
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observed at the protein level (Figure 4c) and correlated with
enhanced reactive oxygen species (ROS) levels under basal
conditions and in response to TGF-β (Figure 4e). In Huh7,
overexpression of CAV1 induced a decrease in NOX4 protein
levels, including upon TGF-β stimulation (Figure 4d), which
correlated with a decrease in ROS levels and lack of response
to TGF-β in terms of ROS production (Figure 4f). Worthy to
mention that silencing CAV1 in HLE cells increased basal
NOX4 levels (in the absence of TGF-β), correlating with higher
ROS, and overexpressing CAV1 in Huh7 decreased NOX4
levels both at the mRNA and protein level, correlating with
decreased ROS. Thus, basal NOX4 expression is also
influenced by the CAV1 levels.
Together, these data suggest that high expression of CAV1
in HCC cells impairs the induction of NOX4 expression by
TGF-β and the consequent ROS-dependent upregulation of
pro-apoptotic genes, in particular BMF.
CAV1 is required for TGF-β-induced epidermal growth
factor receptor (EGFR)-mediated survival signals in HCC
cell lines. Previous studies had revealed that in hepatocytes
and liver tumour cells, upregulation of NOX4 by TGF-β
depends on both canonical Smad-dependent, as well as
other non-canonical pathways. Indeed, NOX4 is upregulated
by TGF-β through a Smad-dependent mechanism, but
transactivation of the EGFR by TGF-β impairs its effects on
NOX4 expression in a PI3K-dependent mechanism.20 For
this reason, we evaluated the role of CAV1 on TGF-β-induced
EGFR activation in HCC cells. In HLE cells, we observed
subtle EGFR activation after TGF-β treatment, which further



























































































Figure 1 CAV1 expression interferes with TGF-β-induced apoptosis in HCC cell lines. HLE parental, HLE shControl, HLE shCAV1, Huh7 parental, Huh7 +pControl and Huh7
+pCAV1 were treated with TGF-β (5 ng/ml) at the times shown after previous FBS starvation (2% FBS; 4 h). (a) Immunoblot of total protein extracts; α-TUBULIN as loading
control. A representative experiment is shown. (b and c) Cell viability measured using Trypan blue staining and expressed as percentage of non-viable cells (N= 4 for b and N= 3
for c). (d and e) Caspase-3 activity, expressed as fold induction versus an untreated control (N= 6 for d and N= 5 for e). Results are expressed as mean± S.E.M. Statistical
comparison uses two-way ANOVA with Sidak post-hoc test as shown in the figure: *Po0.05, **Po0.01, ***Po0.001
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Figure 2 CAV1 expression levels in HCC cell lines determine the clonogenic ability in presence of TGF-β and alter their migratory capacity. (a and b) HLE parental, HLE
shControl, HLE shCAV1, Huh7 parental, Huh7 +pControl and Huh7 +pCAV1 were treated with TGF-β (5 ng/ml) for 1 week in complete medium (10% FBS). Crystal violet stained
colonies indicate clonogenic growth; a representative experiment is shown (left), and quantification is presented from three independent experiments (right). (c and d) Cell
migration in real-time was analysed by the xCELLigence RTCA. Cells were treated with TGF-β (2 ng/ml) for 72 h. Migration rate was determined by analysing the slope of the
lineal interval, between 10 and 35 h in HLE cells and between 15 and 35 h in Huh7 cells (N= 6 from two independent experiments). Results are expressed as mean± S.E.M.
Statistical comparison uses two-way ANOVA with Sidak post-hoc test as shown in the figure: *Po0.05, **Po0.01, ***Po0.001
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Table 1 Caveolin-1 expression levels in HCC cell lines do not impact TGF-β-induced cell cycle arrest
Parental shControl shCAV1
Untreat. 48h TGF-β 48h Untreat. 48h TGF-β 48h Untreat. 48h TGF-β 48h
(a) HLE
G0/G1 65.15±2.14 58.86±1.27 47.86±2.16 45.13± 1.56 65.27±3.90 60.01±1.76
S 13.29±1.33 18.14±0.69 6.96±0.42 8.96± 0.73 13.66±0.65 18.87±1.01
G2/M 19.27±0.63 20.43±0.70 41.76±2.23 41.33± 2.59 16.68±0.85 18.80±0.59
Parental +pControl +pCAV1
Untreat. 48h TGF-β 48h Untreat. 48h TGF-β 48h Untreat. 48h TGF-β 48h
(b) HUH7
G0/G1 65.88± 3.48 76.25±0.04 57.43±2.39 68.42±2.02* 59.59± 1.20 74.43± 2.97*
S 15.75± 3.66 8.35±1.49 15.08±2.98 6.23±1.27 21.94± 1.52 9.30± 1.37**
G2/M 16.70± 0.34 8.65±1.09 24.73±1.69 16.77±0.78* 16.89± 0.43 12.76± 0.72*
HLE parental, HLE shControl, HLE shCAV1, Huh7 parental, Huh7 +pControl and Huh7 +pCAV1 were treated with TGF-β (5 ng/ml) for 48 h after previous FBS
starvation (2% FBS; 4 h). (a and b) Quantification of cell cycle phases (G0/G1, S and G2/M), expressed as mean±S.E.M. (N= 3). Statistical comparison using
Student’s t-test to compare control versus TGF-β treatment in each cell line: *Po0.05, **Po0.01
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Figure 3 Expression of BCL-2 family genes is altered by CAV1 in HCC. HLE shControl, HLE shCAV1, Huh7 +pControl and Huh7 +pCAV1 were treated with TGF-β (2 ng/ml)
at the times shown after previous FBS starvation (2% FBS; 4 h). (a and b) Relative expression levels of BMF and BIM; L32 was used as house-keeping gene (N= 2). Results are
expressed as mean± S.E.M. (c) Upper panel: immunoblot of total protein extracts; β-ACTIN is presented as loading control. A representative experiment is shown (N= 3). Lower
panel: densitometric analysis of BIM relative levels; results are mean± S.E.M. of three independent experiments and are expressed as absolute values. Statistical comparison
was done by two-way ANOVA with Sidak post-hoc test as shown in the figure: *Po0.05, **Po0.01, ***Po0.001
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resulted in activation of the PI3K pathway (Figure 5a). This
effect was inhibited in CAV1-suppressed HLE cells
(Figure 5a), indicating that CAV1 expression is required for
EGFR transactivation by TGF-β. In Huh7 cells, no EGFR
transactivation is observed upon TGF-β stimulation
(Figure 5b), in line with this cell line’s high sensitivity to
TGF-β-mediated cell death. CAV1 overexpression sensitised
Huh7 cells to TGF-β/EGFR phosphorylation pathway branch
(Figure 5b). Furthermore, in HLE, TGF-β-induced AKT
survival signalling was blunted upon CAV1 depletion,
whereas TGF-β-mediated inhibition of AKT phosphorylation
in Huh7 was abrogated upon CAV1 overexpression. These
results suggest that CAV1 is required for TGF-β activation
of non-canonical pathways that mediate anti-apoptotic
signals.
Worthy no note that silencing CAV1 decreased cell
proliferation in HLE cells in presence of FBS or the EGFR
ligand heparin binding EGF-like growth factor (HB-EGF)
(Supplementary Figure 2A) and CAV1-overexpressing Huh7
cells showed a higher proliferation rate in comparison with
control cells (Supplementary Figure 2B). Therefore, these
data suggest that CAV1 confers to the HCC cells advantages
in terms of proliferation, probably facilitating response to
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Figure 4 NOX4 upregulation after TGF-β treatment in HCC cell lines is decreased by CAV1. HLE shControl, HLE shCAV1, Huh7 +pControl and Huh7 +pCAV1 were treated
with TGF-β (2 ng/ml) at the times shown after previous FBS starvation (2% FBS; 4 h). (a and b) Relative expression levels of NOX4; L32 was used as house-keeping gene
(N= 3). Results are expressed as mean±S.E.M. (c and d) Immunoblot of total protein extracts; β-ACTIN was used as loading control. A representative experiment is shown,
whose quantification (densitometry of the specific band relative to the β-ACTIN levels) is incorporated below the band. (e and f) Amplex Ultra Red Fluorescence as a measure of
ROS production, expressed as relative percentage versus untreated HLE shControl cells or Huh7 pControl cells (N= 6 from two independent experiments). Statistical
comparison was done using two-way ANOVA with Sidak post-hoc test as shown in the figure: *Po0.05, **Po0.01, ***Po0.001
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CAV1 is overexpressed in tumoural tissues from HCC
patients and its expression correlates with TGFB1
levels. We finally decided to examine the potential transla-
tional relevance of the previous results in HCC. We analysed
the expression of CAV1 and TGFB1 in a cohort of 65 HCC
patients, in tumoural and surrounding areas. Tumoural tissue
presented higher expression levels of CAV1 compared with
surrounding non-tumoural tissue (Figure 6a and b). Moreover,
we found a significant positive correlation among the
changes in the expression of CAV1 and TGFB1 (Figure 6c).
From public data (Mas Liver Dataset from Oncomine:
Supplementary Figure 3), we found that expression of TGFB1
and CAV1 increased from the cirrhotic status and correlated
with virus hepatitis C (VHC) infection. These data indicate
that co-expression of CAV1 and TGFB1 frequently occurs
in HCC.
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Figure 5 CAV1 facilitates EGFR/AKT survival axis in HCC cells. HLE shControl, HLE shCAV1, Huh7 +pControl and Huh7 +pCAV1 were treated with TGF-β (2 ng/ml in a or
5 ng/ml in b) or HB-EGF (20 ng/ml) at the times shown after previous FBS starvation (2% FBS; 4 h). (a and b) Immunoblot of total protein extracts; α-TUBULIN was used as
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Figure 6 Analysis of CAV1 and TGFB1 expression in HCC tumoural and non-tumoural tissues. qRT-PCR analysis of mRNA levels of CAV1 in non-tumoural and tumoural
tissue. (a) Detail of the relative expression of each one of the HCC tumour tissues analysed versus its respective surrounding tissue (n= 65). Black line represents cut-off (relative
expression= 1). (b) Each dot represents relative expression of each HCC tumour tissue versus its respective surrounding tissue. Statistical comparison was done using Wilcoxon
matched-pairs signed rank test: *Po0.05. (c) Spearman correlation analysis among TGFB1 and CAV1 expression analysed by qRT-PCR in the cohort of 65 samples from
HCC patients
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Altogether, our results indicate that CAV1 expression
increases during HCC progression, coinciding with enhanced
TGFB1 levels. Under these circumstances, CAV1 could
mediate survival in liver tumour cells through its interaction
with the EGFR pathway, which impairs NOX4 upregulation by
TGF-β and BMF-dependent apoptosis (Figure 7).
Discussion
TGF-β signalling participates in all stages of liver disease
progression, from initial damage via inflammation and fibrosis
to cirrhosis and cancer. During liver tumourigenesis, TGF-β
may behave as a suppressor factor at early stages; however,
strong evidences suggest that overactivation of its signalling
could later contribute to tumour progression, once cells
escape from its cytostatic effects.21 For these reasons,
targeting the TGF-β signalling pathway is being explored to
counteract liver disease progression.22
Similarly, different evidences indicate that CAV1 may also
act both as tumour-suppressor or pro-tumourigenic protein.23
Mechanisms underlying such pleiotropic, and sometimes
antagonistic, effects of CAV1 function is a research line of
great interest.24,25 Anti-apoptotic functions of CAV1 have been
reported in different experimental models.3 Related to liver
tumour cells, CAV1 may block apoptosis under stress
conditions, that is, in serum-deprived media, in the human
hepatoblastoma HepG2 cells.26 CAV1 also confers resistance
to anoikis in hepatoma cells by activating the insulin-like
growth factor-1 pathway.27 However, little is known about how
CAV1 may regulate TGF-β-induced apoptosis in liver cells.
Here, we show that in a well-differentiated HCC cell line that
does not express CAV1 and which is sensitive to the pro-
apoptotic effect of TGF-β, ectopic overexpression of CAV1
counteracts suppressive TGF-β stimuli. On the contrary, in a
poorly differentiated HCC cell line with high CAV1 expression,
knockdown of this protein increases susceptibility to TGF-β-
mediated cell death. Importantly, CAV1 expression does not
have any effect on the suppressor response to TGF-β on cell
cycle arrest. Resistant HLE cells are not sensitised for TGF-β-
mediated inhibition of cell proliferation uponCAV1 knockdown.
Further, ectopic CAV1 expression, which significantly counter-
acts TGF-β anti-apoptotic signals in Huh7, has no obvious
impact on TGF-β-mediated cell cycle arrest. However, the
remarkable results obtained on clonogenic growth prove that
CAV1 mediated resistance to TGF-β-induced cell death in
HCC cells has marked consequences with regard to loss of
response to the suppressor effects of this cytokine. These
results indicate that apoptosis is the main anti-tumourigenic
effect of TGF-β in HCC cells. Furthermore, CAV1 is required to
allow cells to respond to this cytokine inducing cell migration.
Indeed, CAV1 switches the function of TGF-β from suppressor
to pro-tumourigenic.
Figure 7 CAV1 orchestrates the TGF-β response in HCC. Whereas in healthy liver, CAV1 levels are very low, its expression increases through the hepatocarcinogenic
process, being very high in poorly differentiated liver tumour cells (i.e., HLE). In those late stage liver tumour cells, high expression of CAV1 inhibits TGF-β-induced apoptosis
through its interaction with the EGFR pathway, which impairs NOX4 upregulation by TGF-β and BMF-dependent apoptosis
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We also show that in HLE cells, downregulation of CAV1
promotes TGF-β-mediated induction of pro-apoptotic BMF,
whereas on the contrary, in Huh7 cells overexpression of
CAV1 reduces TGF-β-induced BMF expression. We also
observe regulation of BIM, particularly at the protein levels,
indicating that its regulation is at least partly post-
transcriptional. These results correlate with previous findings,
showing that CAV1 regulates expression of BCL-2 family
proteins in hepatocytes.15 TGF-β exerts its pro-apoptotic
effects in hepatocytes also through induction of NOX4, which
producesROSand oxidative stress.20,28 An influence of NOX4
on regulation of members of the BCL-2 family was previously
suggested.8,18 Here we propose that basal levels of NOX4 in
HCC cells are influenced by CAV1 levels. More interestingly
for our study, induction of NOX4 by TGF-β depends on CAV1
expression levels. Indeed, overexpression of CAV1 substan-
tially blocks NOX4 induction, whereas CAV1 knockdown
shows the opposite effect. Hence, mechanisms that counter-
act TGF-β-induced NOX4 expression are facilitated by
upregulated CAV1.
TheEGFR pathway is a crucial mechanism, bywhich TGF-β
mediates cell survival in hepatocytes,29 and previous results
indicate that CAV1 is required for this connection.16,30 EGF
counteracts NOX4 upregulation by TGF-β in hepatocytes,20
whereas, in contrast, different evidences indicate that EGFR
inhibition induces expression ofNOX4.31,32 Here we show that
CAV1 silenced HLE cells show attenuation in TGF-β-induced
EGFR transactivation and activation of the PI3K/AKT pathway.
On the contrary, Huh7 cells, which do not respond to TGF-β
activating the EGFR pathway, acquire the capacity to do so,
when CAV1 is overexpressed. These results indicate that the
important role proposed for CAV1 in mediating the EGFR non-
canonical signalling pathway of TGF-β in hepatocytes15,16 is
also present in liver tumour cells. As a consequence, our data
suggest that the level of CAV1 expression in HCC patients
may be an important determinant for defining the tumour cell
response to TGF-β signalling. In this sense, here we show
evidences for a positive correlation between the changes in
the expression of CAV1 and TGFB1 in a cohort of HCC
patients. Expression of TGFB1 and CAV1 increases from the
cirrhotic status and correlated with VHC infection. These data
indicate that co-expression of CAV1 and TGFB1 frequently
occurs in HCC, as was previously suggested in other kind of
tumours, such as prostate cancer.33 This would have marked
consequences on the HCC cell response to TGF-β. As
previously mentioned, CAV1 overexpression is associated
with HCC tumourigenesis and metastasis.4–6 Here we
proposed for the first time that CAV1 could mediate its action
in HCC, at least in part, through modulating tumour cell
response to TGF-β.
In conclusion, our results suggest that high expression of
CAV1 in liver tumour cells triggers switching the response of
TGF-β from a suppressor to a tumourigenic factor. As further
knowledge about the mechanisms that favour the pro-
tumourigenic actions of TGF-β is requested for rationalising
TGF-β directed drugs to treat HCC in human, we suggest
expression of CAV1 as a potential molecular marker for better
stratification of patients prone for such therapy.
Materials and Methods
Reagents and antibodies. Human recombinant TGF-β1 was from
Calbiochem (La Jolla, CA, USA) or from Peprotech (Hamburg, Germany). Foetal
bovine serum (FBS) was from Sera Laboratories International (Cinder Hill, UK).
Anti-NOX4 rabbit polyclonal antiserum was raised by Sigma–Genosys (Suffolk, UK)
against a peptide corresponding to the C-terminal loop region (amino acids
499–511). Specificity was tested by ELISA with the purified peptide.18 This NOX4
antibody is currently available from Merck Millipore (Billerica, MA, USA; cat. no.
ABC459). The other antibodies used were: mouse anti-β-ACTIN (clone AC-15) from
Sigma-Aldrich (St. Louis, MO, USA); rabbit anti-phospho-AKT (Ser473) (D9E) XP,
rabbit anti-AKT, rabbit anti-phospho-EGFR (Tyr1068) (D7A5) XP and rabbit anti-
EGFR were from Cell Signaling Technology (Beverly, MA, USA); mouse anti-CAV1
and rabbit anti-BIM were from BD Pharmingen (Franklin Lakes, NJ, USA); mouse
anti-α-TUBULIN (4G1I) was from AbCam (Cambridge, UK). Secondary antibodies:
ECL mouse IgG, and rabbit IgG, HRP-linked antibodies from GE Healthcare
(Buckinghamshire, UK).
Ethics statement in the work with human HCC tissues. Human
tissues were collected with the required approvals from the Institutional Review
Board (Comité Ético de Investigación Clínica, Hospital Universitario de Bellvitge)
and patient's written consent conformed to the ethical guidelines of the 1975
Declaration of Helsinki. A total of 65 patients were included in the study and both
tumour and non-tumour tissues were collected.
Cell culture conditions. The HCC cell lines HLE and Huh7 were obtained
from the Japanese Collection of Research Bioresources (JCRB) Cell Bank (Osaka,
Japan). For cell culture, cells were grown in Dulbecco’s modified Eagle’s medium
from Lonza (Basel, Switzerland), supplemented with 10% FBS, penicillin (120 μg/
ml), streptomycin (100 μg/ml) and amfoterycin B (2.5 μg/ml) and maintained in a
humidified atmosphere of 37ºC, 5% CO2. For experiments, cells at 60% confluence
were serum starved (2% FBS) for 4 h and treated with TGF-β1 (2 ng/ml –
Calbiochem or 5 ng/ml – PeproTech).
Stable knockdown and overexpression of CAV1. Lentiviral constructs
of GFP+ CAV1 overexpression and knockdown (shCAV1) with their respective non-
targeting controls, were kind gifts from Dr. Carsten Herskind (Universitätsklinikum,
Mannheim, Germany). To generate stable cells, we transduced Huh7 (low CAV1
expressing) with CAV1 overexpression vector, whereas knockdown was achieved in
HLE, which constitutively express high level of CAV1. For transduction, sub-
confluent cells were seeded in complete growth media (12-well multiwell plate) and
cultured overnight. The next day, the culture media were aspirated off and replaced
with a fresh one containing polybrene to a final concentration of 8 μg/ml. Lentiviral
particles were then added to the respective wells at a multiplicity of infection
(MOI) of 10. After overnight culture, we remove the media, replaced with normal
culture media and further incubated the cells for another 24 h before expansion.
Positive cells were selected by fluorescent activated cell sorting (FACS) using
BD FACSAria I (BD Bioscience, Heidelberg, Germany).
Analysis of cell viability. Cell viability was analysed using Trypan blue. Cells
were trypsinised while collecting the media. After 5- min centrifugation at 1200 r.p.
m., cells were resuspended in 50 μl PBS + 1:10 v/v Trypan blue. Viable and non-
viable (blue dyed) cells were counted in a Neubauer chamber, counting eight
squares for condition, with duplicates. Results are expressed as percentage of non-
viable cells.
Crystal violet assay. Cells were stained with crystal violet solution
(0.2% (w/v) in 2% ethanol). Stained cells were lysed by adding SDS 10%. By
spectrophotometric analysis, the absorbance was measured at 595 nm. Results
were expressed as percentage of viable cells versus untreated control in each
condition or time zero.
Analysis of caspase-3 activity. Fluorimetric analysis of caspase-3 activity
was determined using the caspase-3 fluorogenic substrate AC-DEVD-AFC from
Biomol (Hamburg, Germany). Briefly, after TGF-β treatment, media were collected
and dead cells on it were centrifuged at 2000 r.p.m. for 5 min at 4 °C. Then cells on
the plate were washed with HBSS and scrapped in 100 μl of lysis buffer (50 mM
HEPES, 100 mM NaCl, 0.1% CHAPS, 1 mM DTT, 100 μM EDTA, pH 7.4). Cells
from both media and plate were assembled in the same tube. Afterward 20 μl of
protein lysate were mixed with 70 μl of reaction buffer (50 mM HEPES, 100 mM
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NaCl, 0.1% CHAPS, 10 mM DTT, 100 μM EDTA, 10% glycerol, pH 7.4) and finally
10 μl of substrate were added (previously diluted 1 : 20 in reaction buffer) and
plated into a 96-well plate that was incubated at 37 °C for 60 and 120 min, at these
times fluorescence was measured at excitation 400 nm and emission 505 nm.
Protein concentration was determined using a Bio-Rad commercial kit (Munich,
Germany). Results were calculated as fluorescence units per μg of protein and then
expressed as fold induction versus untreated control.
Clonogenic assay. Low number of cells (500 for HLE and 1000 for Huh7 cells
per well) were plated in 12-well multiwell plates (22.1 mm diameter wells). TGF-β
was added in complete media (10% FBS), and it was maintained during 1–2 weeks
(changing media every third day). After the time of culture required the cell media
were removed, cells were washed twice with HBSS and the remaining viable
adherent cells were stained with crystal violet solution.
DNA content/cell cycle analysis. After incubation with TGF-β, cell media
were recovered, so detached cells were taken, and the remaining cells on the plate
were washed twice with PBS. Then, cells were detached using Trypsin-EDTA
(0.05%) and added to the recovered media for centrifugation (5 min at 1500 r.p.m.).
The pellet was resuspended in 300 μl of PBS 1X and was added drop by drop into
70 μl of cold (stored at –20 ºC) 100% ethanol, in constant motion (gently applied
with a vortex), in order to fix cells. At this point, samples were stored at –20 °C.
Then, samples were centrifuged at 1500 r.p.m. during 5 min at 4°C. The pellet was
washed twice in HBSS and finally air-dried and resuspended in 250 μl PBS
containing 10 μg/ml of RNAse. After incubation during 20 min at 37 °C, propidium
iodide (PI) was added at a final concentration of 0.01 mg/ml. Following this process,
PI incorporation was directly proportional to the amount of DNA contained by each
cell. Finally, this suspension was analysed in a flow cytometer BD FACS Canto II
from Becton-Dickinson (BD Bioscience). Cell cycle analysis was carried out using
the software BD FACSDIVA from BD Biosciences (Franklin Lakes, NJ, USA). DNA
content: 2C: G0/G1 phases; 4C: G2/M phases; 42C and o4C: S phase.
RNA isolation, cDNA synthesis and qRT-PCR. E.Z.N.A. Total RNA Kit
II (Omega Bio-Tek, Norcross, GA, USA) was used for total RNA isolation from both,
cell lines and human tissues. Reverse transcription (RT) was carried out using the
High Capacity Reverse Transcriptase kit (Applied Biosystems, Foster City, CA,
USA), with 500 ng of total RNA from each sample for complementary DNA
synthesis. For Real-Time quantitative PCR, expression levels were determined in
duplicate in a LightCycler 480 System, using LightCycler 480 SYBR Green I Master
















Immunoblot analysis. Total protein extracts and western blot procedure were
carried out as previously described.34,35 Primary antibodies were used at 1 : 1000,
except β-actin (1 : 5000). Secondary antibodies were used at 1 : 5000. Protein
concentration was measured using a Bio-Rad commercial kit. Densitometric
analysis of protein bands intensity was performed using ImageJ software (NIH,
Bethesda, MD, USA).
Reactive oxygen species analysis. Extracellular H2O2 was measured in
intact cells using horseradish peroxidase-linked Amplex Ultra Red (Invitrogen,
Carlsbad, CA, USA). Briefly, Amplex Ultra Red (50 μM for HLE cells and 100 μM for
Huh7 cells) and horseradish peroxidase (0.1 U/ml for HLE cells and 0.2 U/ml Huh7
cells) were added to the cellular samples for 2 h. Fluorescence readings were made
at the times indicated in the corresponding figure, in duplicate in a 96-well plate at
ex/em 530/590 nm using 100 μl samples of medium. Fluorescence was measured
in a Fluostar Optima microplate fluorescence reader (from BMG LABTECH,
Ortenberg, Germany) and expressed as percentage of control after correction for
cell number (crystal violet assay) with Amplex Ultra Red.
Real-time migration assay. xCELLigence System was used for real-time
monitoring of cell migration. CIM plates (ref. 05 665 817 001, ACEA Biosciences,
Inc., San Diego, CA, USA) were placed onto the Real-Time Cell Analyzer (RTCA)
station (xCELLigence System, Roche, Mannheim, Germany) for monitoring cell
migration. First, both sides of the membrane were coated with collagen type IV
solution (25.5 μg/cm2) (ref. C7521, Sigma-Aldrich). In all, 100μl of a suspension
containing 4x105 cells/ml with 2% FBS were seeded onto the top chamber of a CIM
plate and treated with TGF-β. The lower chamber contained medium with 10% FBS
as a chemoattractant. Cell migration was continuously monitored throughout the
experiments by measuring changes in the electrical impedance at the electrode/cell
interface, as a population of cells migrated from the top to the bottom chamber.
Continuous values every 15 min were represented as cell index (CI), a
dimensionless parameter, which reflects a relative change in measured electrical
impedance, and quantified as a slope (h-1) of the first hours.
Statistics. All data represent at least three experiments and are expressed as
the mean ± S.E.M. Differences between groups were compared using Student’s t-
test (when comparing two groups), one-way ANOVA with Tukey’s multiple
comparison test (when comparing more than two groups and considering one
independent variable), or two-way ANOVA with Sidak post-hoc test (when
comparing differences between groups considering two independent variables).
For patient samples, statistical comparison was done using Wilcoxon matched pairs
signed rank test and the Spearman correlation analysis. All statistical tests were
conducted using GraphPad Prism (GraphPad, San Diego, CA, USA). Differences
were considered statistically significant at *Po0.05, **Po0.01 and ***Po0.001.
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